Clinical Efficacy of Platinum Antineoplastic Drugs in the Treatment of Gynecological Tumors
This article retrospectively analyzed the treatment of patients with ovarian cancer admitted between August 2013 and August 2018. To study the efficacy of platinum anticancer drugs for ovarian cancer All patients underwent primary cytoreductive surgery. According to the different types of advanced chemotherapy, they were divided into TC group (paclitaxel plus carboplatin) group and PC group (cyclophosphamide combined with cisplatin group). 80 patients in the TC group and 80 patients in the PC group were randomly selected. Follow-up patients' survival status. The short-term efficacy and 5-year survival rate of the two groups were used as evaluation indicators. The results showed that 70 patients in the TC group were effective in the near future with an effective rate of 87%. 35 patients survived for 5 years and the 5-year survival rate was 43.8%. Sixty-five patients in the PC group were effective in the near future with an effective rate of 83%. Thirty-two patients survived for 5 years and the 5-year survival rate was 40.0%. There was no significant difference in treatment efficiency and 5-year survival rate between the TC group and the PC group (p>0.05). Through this study, it was found that platinum drugs have obvious curative effect on ovarian cancer and have clinical promotion value.